Product Description
Meclocycline sulfosalicylate is a broad spectrum antimicrobial agent that was synthesized in 1960 and has been marketed abroad for several years. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/6452987/)
Mechanisms of Action: Protein Synthesis Inhibitor,30S Ribosomal Subunit Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Ireland | New Zealand
Approved Indications: None
Known Adverse Events: None
Company: Mucosal
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Mucositis|Stomatitis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
SNX-1012-CLN2-006 | P2 |
Completed |
Stomatitis|Mucositis |
2008-05-01 |